GlassScriptPhysician profile
Anton C Vasiliu
NPI 1558356170
$8,056.78
in general payments reported to CMS, 2019-2025
48 companies · $1,160 in 2025
The $1,160 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,420 · 2020: $951 · 2021: $1,047 · 2022: $989 · 2023: $1,339 · 2024: $1,150 · 2025: $1,160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,569 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,569.00 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $909.38 | 2019-2024 | Xarelto |
| Amgen INC. | $837.31 | 2019-2025 | Evenity, Repatha, Prolia |
| Pfizer INC. | $571.63 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $540.69 | 2021-2025 | |
| Lilly USA, LLC | $536.19 | 2019-2025 | Mounjaro, Jardiance, Kisunla |
| Abbvie INC. | $472.36 | 2021-2025 | Qulipta |
| Astrazeneca Pharmaceuticals LP | $428.39 | 2019-2025 | Farxiga, Airsupra, Lokelma |
| Novartis Pharmaceuticals Corporation | $399.22 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $352.43 | 2019-2025 | Jardiance, Tradjenta, Ofev |
| Teva Pharmaceuticals USA, INC. | $301.23 | 2022-2025 | Austedo Xr, Austedo, Austedo Xr |
| Astellas Pharma US INC | $233.41 | 2019-2025 | Veozah, Myrbetriq |
| Sunovion Pharmaceuticals INC. | $227.41 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $194.30 | 2019-2023 | |
| Eisai INC. | $194.22 | 2020-2025 | |
| Novo Nordisk INC | $186.91 | 2020-2025 | Ozempic, Rybelsus |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anton Vasiliu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.